Pipkorn U, Pukander J, Suonpää J, Mäkinen J, Lindqvist N
Ear, Nose and Throat Department of University Hospital, Lund, Sweden.
Clin Allergy. 1988 May;18(3):253-9. doi: 10.1111/j.1365-2222.1988.tb02867.x.
The effects of prolonged treatment with intranasally applied budesonide was studied in twenty-four patients with perennial allergic or non-allergic rhinitis. Patients on continuous treatment were followed up for 5.5 years. At entry and follow-up visits, rhinoscopic findings, nasal symptom scores, blood chemistry, haematology, urine analysis and determination of plasma cortisol levels, before and after stimulation with ACTH (Synacthen, Ciba-Geigy AG, Basel, Switzerland), were registered. Biopsies of the nasal mucosa were taken before entry into the study, after 1 year of treatment, and after varying time intervals ranging from 2.5 to 5.5 years during the treatment. The biopsy specimens were examined blindly by an independent pathologist. The analyses revealed no histopathological changes in the nasal mucosa. All nasal symptom parameters assessed by the patients were significantly reduced from the baseline during the entire follow-up period. No clinically significant changes in the haematological and blood chemistry parameters were observed. Plasma cortisol analyses before and after challenge with ACTH revealed no influence on the hypothalamic pituitary adrenal (HPA) axis. The present study suggests that intranasal budesonide in the dose of 200-400 micrograms/day is also a safe treatment for prolonged treatment of perennial rhinitis.
对24例常年性变应性或非变应性鼻炎患者进行了鼻内应用布地奈德长期治疗效果的研究。持续治疗的患者随访了5.5年。在入组时和随访时，记录鼻镜检查结果、鼻部症状评分、血液化学指标、血液学指标、尿液分析以及促肾上腺皮质激素（瑞士巴塞尔汽巴 - 嘉基公司生产的Synacthen）刺激前后血浆皮质醇水平的测定结果。在入组研究前、治疗1年后以及治疗期间2.5至5.5年不等的不同时间间隔后，取鼻黏膜活检组织。活检标本由一名独立病理学家进行盲法检查。分析显示鼻黏膜无组织病理学改变。在整个随访期间，患者评估的所有鼻部症状参数均较基线水平显著降低。未观察到血液学和血液化学参数有临床显著变化。促肾上腺皮质激素激发前后的血浆皮质醇分析显示对下丘脑 - 垂体 - 肾上腺（HPA）轴无影响。本研究表明，每日剂量为200 - 400微克的鼻内布地奈德也是常年性鼻炎长期治疗的一种安全疗法。
